APA (7th ed.) Citation

Zhang, Q., Wang, Z., Zeng, X., Ding, Y., & Wang, C. (2025). Evaluation of tumorous LCP1 and ADPGK as predictive biomarker for immune-related adverse events in bone and soft tissue sarcomas treated with anti-PD-1 and anti-PD-L1 antibodies. BMC Cancer, 25(1), 1. https://doi.org/10.1186/s12885-025-14007-0

Chicago Style (17th ed.) Citation

Zhang, Qing, Zhe Wang, Xueqin Zeng, Yi Ding, and Chen Wang. "Evaluation of Tumorous LCP1 and ADPGK as Predictive Biomarker for Immune-related Adverse Events in Bone and Soft Tissue Sarcomas Treated with Anti-PD-1 and Anti-PD-L1 Antibodies." BMC Cancer 25, no. 1 (2025): 1. https://doi.org/10.1186/s12885-025-14007-0.

MLA (9th ed.) Citation

Zhang, Qing, et al. "Evaluation of Tumorous LCP1 and ADPGK as Predictive Biomarker for Immune-related Adverse Events in Bone and Soft Tissue Sarcomas Treated with Anti-PD-1 and Anti-PD-L1 Antibodies." BMC Cancer, vol. 25, no. 1, 2025, p. 1, https://doi.org/10.1186/s12885-025-14007-0.